Company intelligence / Profile preview

NanoCureTech

Seoul, Seoul Special City, South Koreaimperialmotion.com ↗

Ownership: Private
Development stage: Other

Overview

NanoCureTech has developed a proprietary nanopowder manufacturing platform enabling the creation of nanosized antioxidants and other bioactive compounds. Their flagship product, NBF Gingival Gel, uses these nanoparticles for improved oral tissue penetration and sustained release. Clinical case reports suggest efficacy in oral wound healing. The company is also engaged in research on new drugs using its nanotechnology platform.

Therapeutic areas: Other
Modalities: NanoparticleNanopowderSmall moleculeTopical gel
Industry: Biotech

Drug pipeline

1 asset

NBF Gingival Gel

Partnerships

Open to business partners interested in applying their nanopowders or collaborating on studies; no major pharma partnerships listed

Beyond the preview

Go deeper on NanoCureTech.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NanoCureTech.

Explore the full profile